Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 80

1.

ERβ1: characterization, prognosis, and evaluation of treatment strategies in ERα-positive and -negative breast cancer.

Reese JM, Suman VJ, Subramaniam M, Wu X, Negron V, Gingery A, Pitel KS, Shah SS, Cunliffe HE, McCullough AE, Pockaj BA, Couch FJ, Olson JE, Reynolds C, Lingle WL, Spelsberg TC, Goetz MP, Ingle JN, Hawse JR.

BMC Cancer. 2014 Oct 7;14:749. doi: 10.1186/1471-2407-14-749.

2.

Impact of c-MYC protein expression on outcome of patients with early-stage HER2+ breast cancer treated with adjuvant trastuzumab NCCTG (alliance) N9831.

Dueck AC, Reinholz MM, Geiger XJ, Tenner K, Ballman K, Jenkins RB, Riehle D, Chen B, McCullough AE, Davidson NE, Martino S, Sledge GW, Kaufman PA, Kutteh LA, Gralow J, Harris LN, Ingle JN, Lingle WL, Perez EA.

Clin Cancer Res. 2013 Oct 15;19(20):5798-807. doi: 10.1158/1078-0432.CCR-13-0558. Epub 2013 Aug 21.

3.

Soluble human epidermal growth factor receptor 2 (HER2) levels in patients with HER2-positive breast cancer receiving chemotherapy with or without trastuzumab: results from North Central Cancer Treatment Group adjuvant trial N9831.

Moreno-Aspitia A, Hillman DW, Dyar SH, Tenner KS, Gralow J, Kaufman PA, Davidson NE, Lafky JM, Reinholz MM, Lingle WL, Kutteh LA, Carney WP, Dueck AC, Perez EA.

Cancer. 2013 Aug 1;119(15):2675-82. doi: 10.1002/cncr.28130. Epub 2013 Jun 6.

4.

Impact of PTEN protein expression on benefit from adjuvant trastuzumab in early-stage human epidermal growth factor receptor 2-positive breast cancer in the North Central Cancer Treatment Group N9831 trial.

Perez EA, Dueck AC, McCullough AE, Chen B, Geiger XJ, Jenkins RB, Lingle WL, Davidson NE, Martino S, Kaufman PA, Kutteh LA, Sledge GW, Harris LN, Gralow JR, Reinholz MM.

J Clin Oncol. 2013 Jun 10;31(17):2115-22. doi: 10.1200/JCO.2012.42.2642. Epub 2013 May 6.

5.

Immunohistochemistry and fluorescence in situ hybridization assessment of HER2 in clinical trials of adjuvant therapy for breast cancer (NCCTG N9831, BCIRG 006, and BCIRG 005).

Perez EA, Press MF, Dueck AC, Jenkins RB, Kim C, Chen B, Villalobos I, Paik S, Buyse M, Wiktor AE, Meyer R, Finnigan M, Zujewski J, Shing M, Stern HM, Lingle WL, Reinholz MM, Slamon DJ.

Breast Cancer Res Treat. 2013 Feb;138(1):99-108. doi: 10.1007/s10549-013-2444-y. Epub 2013 Feb 19.

6.

Endoxifen's molecular mechanisms of action are concentration dependent and different than that of other anti-estrogens.

Hawse JR, Subramaniam M, Cicek M, Wu X, Gingery A, Grygo SB, Sun Z, Pitel KS, Lingle WL, Goetz MP, Ingle JN, Spelsberg TC.

PLoS One. 2013;8(1):e54613. doi: 10.1371/journal.pone.0054613. Epub 2013 Jan 28.

7.

Multi-platform analysis of microRNA expression measurements in RNA from fresh frozen and FFPE tissues.

Kolbert CP, Feddersen RM, Rakhshan F, Grill DE, Simon G, Middha S, Jang JS, Simon V, Schultz DA, Zschunke M, Lingle W, Carr JM, Thompson EA, Oberg AL, Eckloff BW, Wieben ED, Li P, Yang P, Jen J.

PLoS One. 2013;8(1):e52517. doi: 10.1371/journal.pone.0052517. Epub 2013 Jan 31. Erratum in: PLoS One. 2014;9(1). doi:10.1371/annotation/7d397301-705d-46bb-92cc-ce725975273a.

8.

Network-based approach identified cell cycle genes as predictor of overall survival in lung adenocarcinoma patients.

Li Y, Tang H, Sun Z, Bungum AO, Edell ES, Lingle WL, Stoddard SM, Zhang M, Jen J, Yang P, Wang L.

Lung Cancer. 2013 Apr;80(1):91-8. doi: 10.1016/j.lungcan.2012.12.022. Epub 2013 Jan 26.

9.

The mitotic kinase Aurora--a promotes distant metastases by inducing epithelial-to-mesenchymal transition in ERα(+) breast cancer cells.

D'Assoro AB, Liu T, Quatraro C, Amato A, Opyrchal M, Leontovich A, Ikeda Y, Ohmine S, Lingle W, Suman V, Ecsedy J, Iankov I, Di Leonardo A, Ayers-Inglers J, Degnim A, Billadeau D, McCubrey J, Ingle J, Salisbury JL, Galanis E.

Oncogene. 2014 Jan 30;33(5):599-610. doi: 10.1038/onc.2012.628. Epub 2013 Jan 21.

10.

Pazopanib enhances paclitaxel-induced mitotic catastrophe in anaplastic thyroid cancer.

Isham CR, Bossou AR, Negron V, Fisher KE, Kumar R, Marlow L, Lingle WL, Smallridge RC, Sherman EJ, Suman VJ, Copland JA, Bible KC.

Sci Transl Med. 2013 Jan 2;5(166):166ra3. doi: 10.1126/scitranslmed.3004358.

11.

North central cancer treatment group (NCCTG) N0537: phase II trial of VEGF-trap in patients with metastatic breast cancer previously treated with an anthracycline and/or a taxane.

Sideras K, Dueck AC, Hobday TJ, Rowland KM Jr, Allred JB, Northfelt DW, Lingle WL, Behrens RJ, Fitch TR, Nikcevich DA, Perez EA.

Clin Breast Cancer. 2012 Dec;12(6):387-91. doi: 10.1016/j.clbc.2012.09.007. Epub 2012 Oct 17.

12.

Potential for the embryonic morphogen Nodal as a prognostic and predictive biomarker in breast cancer.

Strizzi L, Hardy KM, Margaryan NV, Hillman DW, Seftor EA, Chen B, Geiger XJ, Thompson EA, Lingle WL, Andorfer CA, Perez EA, Hendrix MJ.

Breast Cancer Res. 2012 May 11;14(3):R75.

13.

Quantifying insulin receptor isoform expression in FFPE breast tumors.

Harrington SC, Weroha SJ, Reynolds C, Suman VJ, Lingle WL, Haluska P.

Growth Horm IGF Res. 2012 Jun-Aug;22(3-4):108-15. doi: 10.1016/j.ghir.2012.04.001. Epub 2012 Apr 30.

14.

Development, characterization, and applications of a novel estrogen receptor beta monoclonal antibody.

Wu X, Subramaniam M, Negron V, Cicek M, Reynolds C, Lingle WL, Goetz MP, Ingle JN, Spelsberg TC, Hawse JR.

J Cell Biochem. 2012 Feb;113(2):711-23. doi: 10.1002/jcb.23443.

15.

Cytokeratin-19 and mammaglobin gene expression in circulating tumor cells from metastatic breast cancer patients enrolled in North Central Cancer Treatment Group trials, N0234/336/436/437.

Reinholz MM, Kitzmann KA, Tenner K, Hillman D, Dueck AC, Hobday TJ, Northfelt DW, Moreno-Aspitia A, Roy V, LaPlant B, Allred JB, Stella PJ, Lingle WL, Perez EA.

Clin Cancer Res. 2011 Nov 15;17(22):7183-93. doi: 10.1158/1078-0432.CCR-11-0981. Epub 2011 Oct 5.

16.

Tissue composition of mammographically dense and non-dense breast tissue.

Ghosh K, Brandt KR, Reynolds C, Scott CG, Pankratz VS, Riehle DL, Lingle WL, Odogwu T, Radisky DC, Visscher DW, Ingle JN, Hartmann LC, Vachon CM.

Breast Cancer Res Treat. 2012 Jan;131(1):267-75. doi: 10.1007/s10549-011-1727-4. Epub 2011 Aug 30.

17.

Control of centrin stability by Aurora A.

Lukasiewicz KB, Greenwood TM, Negron VC, Bruzek AK, Salisbury JL, Lingle WL.

PLoS One. 2011;6(6):e21291. doi: 10.1371/journal.pone.0021291. Epub 2011 Jun 23.

18.

Estrogen receptor-beta sensitizes breast cancer cells to the anti-estrogenic actions of endoxifen.

Wu X, Subramaniam M, Grygo SB, Sun Z, Negron V, Lingle WL, Goetz MP, Ingle JN, Spelsberg TC, Hawse JR.

Breast Cancer Res. 2011 Mar 10;13(2):R27. doi: 10.1186/bcr2844.

19.

Quantitative miRNA expression analysis using fluidigm microfluidics dynamic arrays.

Jang JS, Simon VA, Feddersen RM, Rakhshan F, Schultz DA, Zschunke MA, Lingle WL, Kolbert CP, Jen J.

BMC Genomics. 2011 Mar 9;12:144. doi: 10.1186/1471-2164-12-144.

20.

HSulf-1 modulates FGF2- and hypoxia-mediated migration and invasion of breast cancer cells.

Khurana A, Liu P, Mellone P, Lorenzon L, Vincenzi B, Datta K, Yang B, Linhardt RJ, Lingle W, Chien J, Baldi A, Shridhar V.

Cancer Res. 2011 Mar 15;71(6):2152-61. doi: 10.1158/0008-5472.CAN-10-3059. Epub 2011 Jan 25.

21.

C-MYC alterations and association with patient outcome in early-stage HER2-positive breast cancer from the north central cancer treatment group N9831 adjuvant trastuzumab trial.

Perez EA, Jenkins RB, Dueck AC, Wiktor AE, Bedroske PP, Anderson SK, Ketterling RP, Sukov WR, Kanehira K, Chen B, Geiger XJ, Andorfer CA, McCullough AE, Davidson NE, Martino S, Sledge GW, Kaufman PA, Kutteh LA, Gralow JR, Harris LN, Ingle JN, Lingle WL, Reinholz MM.

J Clin Oncol. 2011 Feb 20;29(6):651-9. doi: 10.1200/JCO.2010.30.2125. Epub 2011 Jan 18.

22.

Expression profiling of formalin-fixed paraffin-embedded primary breast tumors using cancer-specific and whole genome gene panels on the DASL® platform.

Reinholz MM, Eckel-Passow JE, Anderson SK, Asmann YW, Zschunke MA, Oberg AL, McCullough AE, Dueck AC, Chen B, April CS, Wickham-Garcia E, Jenkins RB, Cunningham JM, Jen J, Perez EA, Fan JB, Lingle WL.

BMC Med Genomics. 2010 Dec 20;3:60. doi: 10.1186/1755-8794-3-60.

23.

HER2 and chromosome 17 effect on patient outcome in the N9831 adjuvant trastuzumab trial.

Perez EA, Reinholz MM, Hillman DW, Tenner KS, Schroeder MJ, Davidson NE, Martino S, Sledge GW, Harris LN, Gralow JR, Dueck AC, Ketterling RP, Ingle JN, Lingle WL, Kaufman PA, Visscher DW, Jenkins RB.

J Clin Oncol. 2010 Oct 1;28(28):4307-15. doi: 10.1200/JCO.2009.26.2154. Epub 2010 Aug 9.

24.

Comparison of central HER2 testing with quantitative total HER2 expression and HER2 homodimer measurements using a novel proximity-based assay.

Huang W, Reinholz M, Weidler J, Yolanda L, Paquet A, Whitcomb J, Lingle W, Jenkins RB, Chen B, Larson JS, Tan Y, Sherwood T, Bates M, Perez EA.

Am J Clin Pathol. 2010 Aug;134(2):303-11. doi: 10.1309/AJCP3BZY4YAFNTRG.

PMID:
20660336
25.

Aromatase immunoreactivity is increased in mammographically dense regions of the breast.

Vachon CM, Sasano H, Ghosh K, Brandt KR, Watson DA, Reynolds C, Lingle WL, Goss PE, Li R, Aiyar SE, Scott CG, Pankratz VS, Santen RJ, Ingle JN.

Breast Cancer Res Treat. 2011 Jan;125(1):243-52. doi: 10.1007/s10549-010-0944-6. Epub 2010 Jun 5.

26.

A promising approach for treatment of tumor-induced bone diseases: utilizing bisphosphonate derivatives of nucleoside antimetabolites.

Reinholz MM, Zinnen SP, Dueck AC, Dingli D, Reinholz GG, Jonart LA, Kitzmann KA, Bruzek AK, Negron V, Abdalla AK, Arendt BK, Croatt AJ, Sanchez-Perez L, Sebesta DP, Lönnberg H, Yoneda T, Nath KA, Jelinek DF, Russell SJ, Ingle JN, Spelsberg TC, Dixon HB, Karpeisky A, Lingle WL.

Bone. 2010 Jul;47(1):12-22. doi: 10.1016/j.bone.2010.03.006. Epub 2010 Mar 15.

27.

Specific overexpression of cyclin E·CDK2 in early preinvasive and primary breast tumors in female ACI rats induced by estrogen.

Weroha SJ, Lingle WL, Hong Y, Li SA, Li JJ.

Horm Cancer. 2010 Feb;1(1):34-43. doi: 10.1007/s12672-009-0004-z. Epub 2010 Feb 10.

PMID:
21761349
28.

Chronic exposure to zinc chromate induces centrosome amplification and spindle assembly checkpoint bypass in human lung fibroblasts.

Holmes AL, Wise SS, Pelsue SC, Aboueissa AM, Lingle W, Salisbury J, Gallagher J, Wise JP Sr.

Chem Res Toxicol. 2010 Feb 15;23(2):386-95. doi: 10.1021/tx900360w.

29.

Aurora A, centrosome structure, and the centrosome cycle.

Lukasiewicz KB, Lingle WL.

Environ Mol Mutagen. 2009 Oct;50(8):602-19. doi: 10.1002/em.20533. Review.

PMID:
19774610
30.

FKBP51 affects cancer cell response to chemotherapy by negatively regulating Akt.

Pei H, Li L, Fridley BL, Jenkins GD, Kalari KR, Lingle W, Petersen G, Lou Z, Wang L.

Cancer Cell. 2009 Sep 8;16(3):259-66. doi: 10.1016/j.ccr.2009.07.016.

31.

Deficiencies in Chfr and Mlh1 synergistically enhance tumor susceptibility in mice.

Fu Z, Regan K, Zhang L, Muders MH, Thibodeau SN, French A, Wu Y, Kaufmann SH, Lingle WL, Chen J, Tindall DJ.

J Clin Invest. 2009 Sep;119(9):2714-24. doi: 10.1172/JCI37405. Epub 2009 Aug 17.

32.

Phase I trial of autologous hematopoietic SCT with escalating doses of topotecan combined with CY and carboplatin in patients with relapsed or persistent ovarian or primary peritoneal carcinoma.

Litzow MR, Peethambaram PP, Safgren SL, Keeney GL, Ansell SM, Dispenzieri A, Elliott MA, Gastineau DA, Gertz MA, Inwards DJ, Lacy MQ, Micallef IN, Porrata LF, Lingle WL, Hartmann LC, Frost MH, Barrette BA, Long HJ, Suman VJ, Reid JM, Ames MM, Kaufmann SH.

Bone Marrow Transplant. 2010 Mar;45(3):490-7. doi: 10.1038/bmt.2009.181. Epub 2009 Aug 3.

33.

Applications of cellular systems biology in breast cancer patient stratification and diagnostics.

Critchley-Thorne RJ, Miller SM, Taylor DL, Lingle WL.

Comb Chem High Throughput Screen. 2009 Nov;12(9):860-9. Review.

PMID:
19531004
34.

Analysis of gene expression in stage I serous tumors identifies critical pathways altered in ovarian cancer.

Chien J, Fan JB, Bell DA, April C, Klotzle B, Ota T, Lingle WL, Gonzalez Bosquet J, Shridhar V, Hartmann LC.

Gynecol Oncol. 2009 Jul;114(1):3-11. doi: 10.1016/j.ygyno.2009.04.002. Epub 2009 May 1.

PMID:
19410283
35.

Breast cancer and aneusomy 17: implications for carcinogenesis and therapeutic response.

Reinholz MM, Bruzek AK, Visscher DW, Lingle WL, Schroeder MJ, Perez EA, Jenkins RB.

Lancet Oncol. 2009 Mar;10(3):267-77. doi: 10.1016/S1470-2045(09)70063-4. Review.

36.

Racial disparity in breast cancer and functional germ line mutation in galectin-3 (rs4644): a pilot study.

Balan V, Nangia-Makker P, Schwartz AG, Jung YS, Tait L, Hogan V, Raz T, Wang Y, Yang ZQ, Wu GS, Guo Y, Li H, Abrams J, Couch FJ, Lingle WL, Lloyd RV, Ethier SP, Tainsky MA, Raz A.

Cancer Res. 2008 Dec 15;68(24):10045-50. doi: 10.1158/0008-5472.CAN-08-3224.

37.

Phase II trial of sorafenib in patients with metastatic breast cancer previously exposed to anthracyclines or taxanes: North Central Cancer Treatment Group and Mayo Clinic Trial N0336.

Moreno-Aspitia A, Morton RF, Hillman DW, Lingle WL, Rowland KM Jr, Wiesenfeld M, Flynn PJ, Fitch TR, Perez EA.

J Clin Oncol. 2009 Jan 1;27(1):11-5. doi: 10.1200/JCO.2007.15.5242. Epub 2008 Dec 1.

38.

Cisplatin abrogates the geldanamycin-induced heat shock response.

McCollum AK, Lukasiewicz KB, Teneyck CJ, Lingle WL, Toft DO, Erlichman C.

Mol Cancer Ther. 2008 Oct;7(10):3256-64. doi: 10.1158/1535-7163.MCT-08-0157.

39.

Cytochrome P450 2D6 and homeobox 13/interleukin-17B receptor: combining inherited and tumor gene markers for prediction of tamoxifen resistance.

Goetz MP, Suman VJ, Couch FJ, Ames MM, Rae JM, Erlander MG, Ma XJ, Sgroi DC, Reynolds CA, Lingle WL, Weinshilboum RM, Flockhart DA, Desta Z, Perez EA, Ingle JN.

Clin Cancer Res. 2008 Sep 15;14(18):5864-8. doi: 10.1158/1078-0432.CCR-08-0619.

40.

Deregulation of the centrosome cycle and the origin of chromosomal instability in cancer.

Lingle WL, Lukasiewicz K, Salisbury JL.

Adv Exp Med Biol. 2005;570:393-421. doi: 10.1007/1-4020-3764-3_14. Review.

PMID:
18727509
41.

Expression of selected Aurora A kinase substrates in solely estrogen-induced ectopic uterine stem cell tumors in the Syrian hamster kidney.

Hontz AE, Li SA, Salisbury JL, Lingle WL, Li JJ.

Adv Exp Med Biol. 2008;617:411-8. doi: 10.1007/978-0-387-69080-3_39.

PMID:
18497064
42.

Molecular analysis of metaplastic breast carcinoma: high EGFR copy number via aneusomy.

Gilbert JA, Goetz MP, Reynolds CA, Ingle JN, Giordano KF, Suman VJ, Blair HE, Jenkins RB, Lingle WL, Reinholz MM, Adjei AA, Ames MM.

Mol Cancer Ther. 2008 Apr;7(4):944-51. doi: 10.1158/1535-7163.MCT-07-0570.

43.

Association between cyclooxygenase-2 expression in atypical hyperplasia and risk of breast cancer.

Visscher DW, Pankratz VS, Santisteban M, Reynolds C, Ristimäki A, Vierkant RA, Lingle WL, Frost MH, Hartmann LC.

J Natl Cancer Inst. 2008 Mar 19;100(6):421-7. doi: 10.1093/jnci/djn036. Epub 2008 Mar 11.

PMID:
18334709
44.

Stratification of breast cancer risk in women with atypia: a Mayo cohort study.

Degnim AC, Visscher DW, Berman HK, Frost MH, Sellers TA, Vierkant RA, Maloney SD, Pankratz VS, de Groen PC, Lingle WL, Ghosh K, Penheiter L, Tlsty T, Melton LJ 3rd, Reynolds CA, Hartmann LC.

J Clin Oncol. 2007 Jul 1;25(19):2671-7. Epub 2007 Jun 11.

PMID:
17563394
45.

Folate receptor overexpression is associated with poor outcome in breast cancer.

Hartmann LC, Keeney GL, Lingle WL, Christianson TJ, Varghese B, Hillman D, Oberg AL, Low PS.

Int J Cancer. 2007 Sep 1;121(5):938-42.

47.

Loss of HSulf-1 expression enhances autocrine signaling mediated by amphiregulin in breast cancer.

Narita K, Chien J, Mullany SA, Staub J, Qian X, Lingle WL, Shridhar V.

J Biol Chem. 2007 May 11;282(19):14413-20. Epub 2007 Mar 15.

48.

The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen.

Goetz MP, Knox SK, Suman VJ, Rae JM, Safgren SL, Ames MM, Visscher DW, Reynolds C, Couch FJ, Lingle WL, Weinshilboum RM, Fritcher EG, Nibbe AM, Desta Z, Nguyen A, Flockhart DA, Perez EA, Ingle JN.

Breast Cancer Res Treat. 2007 Jan;101(1):113-21. Epub 2006 Nov 18.

PMID:
17115111
49.

HER2 testing by local, central, and reference laboratories in specimens from the North Central Cancer Treatment Group N9831 intergroup adjuvant trial.

Perez EA, Suman VJ, Davidson NE, Martino S, Kaufman PA, Lingle WL, Flynn PJ, Ingle JN, Visscher D, Jenkins RB.

J Clin Oncol. 2006 Jul 1;24(19):3032-8.

PMID:
16809727
50.

The granulin-epithelin precursor is a steroid-regulated growth factor in endometrial cancer.

Jones MB, Houwink AP, Freeman BK, Greenwood TM, Lafky JM, Lingle WL, Berchuck A, Maxwell GL, Podratz KC, Maihle NJ.

J Soc Gynecol Investig. 2006 May;13(4):304-11.

PMID:
16697948

Supplemental Content

Loading ...
Support Center